Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Details Textual)

v3.19.1
Significant Accounting Policies (Details Textual) - USD ($)
1 Months Ended 12 Months Ended
Sep. 30, 2017
Jul. 31, 2017
Jun. 26, 2017
Sep. 30, 2016
Oct. 31, 2015
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Stock Issued During Period, Shares, New Issues       250,000        
Preferred Stock, Dividend Rate, Percentage       2.50%        
Debt Instrument, Decrease, Forgiveness         $ 3,000,000      
Payments to Acquire Investments $ 5,000,000 $ 5,000,000       $ 0    
Short-term Investments           0 $ 10,000,000  
Research and Development in Process           0 1,103,000  
Stockholders' Equity, Reverse Stock Split     presented to reflect the 3.0-to-1.0 reverse stock split.          
Fortress Biotech, Inc [Member]                
Research and Development in Process           $ 0 $ 1,100,000 $ 49,000